Antibody-based depletion of Foxp3+ T cells potentiates antitumor immune memory stimulated by mTOR inhibition

OncoImmunology

Volumn 3, Issue 6, 2014, Pages

  Kim, Hyung L ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

CD4; Memory T cell; mTOR; Regulatory T cells; Tumor immunology

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

ANTIBODY DETECTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; ENZYME INHIBITION; HUMAN; IMMUNOLOGICAL MEMORY; MOLECULAR DYNAMICS; PROTEIN DEPLETION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 84906517329     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.29081     Document Type: Article

References (10)

1. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460:108-12; PMID:19543266; http://dx.doi. org/10.1038/nature08155
2. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, Jones RG, Choi Y. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009; 460:103-7; PMID:19494812; http:// dx.doi.org/10.1038/nature08097
3. Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL. Temsirolimus, an mTOR inhibitor, enhances antitumour effects of heat shock protein cancer vaccines. Br J Cancer 2011; 104:643-52; PMID:21285988; http://dx.doi.org/10.1038/bjc.2011.15
4. Fuse S, Tsai CY, Molloy MJ, Allie SR, Zhang W, Yagita H, Usherwood EJ. Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1. J Immunol 2009; 182:4244-54; PMID:19299723; http://dx.doi.org/10.4049/ jimmunol.0802041
5. Jing W, Yan X, Hallett WH, Gershan JA, Johnson BD. Depletion of CD25+ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. Blood 2011; 117:6952-62; PMID:21521781; http://dx.doi. org/10.1182/blood-2010-12-326108
6. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-710; PMID:23897981; http://dx.doi.org/10.1084/jem.20130579
7. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59:3128-33; PMID:10397255
8. Côté AL, Byrne KT, Steinberg SM, Zhang P, Turk MJ. Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS One 2011; 6:e26491; PMID:22046294; http://dx.doi.org/10.1371/journal.pone.0026491
9. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-33; PMID:16308572; http://dx.doi.org/10.1172/ JCI25947
10. Mahnke K, Schönfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K, Bedke T, Johnson TS, Storn V, Schallenberg S, et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007; 120:2723-33; PMID:17315189; http://dx.doi. org/10.1002/ijc.22617